RU2010119041A - Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи - Google Patents
Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи Download PDFInfo
- Publication number
- RU2010119041A RU2010119041A RU2010119041/15A RU2010119041A RU2010119041A RU 2010119041 A RU2010119041 A RU 2010119041A RU 2010119041/15 A RU2010119041/15 A RU 2010119041/15A RU 2010119041 A RU2010119041 A RU 2010119041A RU 2010119041 A RU2010119041 A RU 2010119041A
- Authority
- RU
- Russia
- Prior art keywords
- solid particle
- enteric coating
- pharmaceutical composition
- active agent
- patient
- Prior art date
Links
- 235000012631 food intake Nutrition 0.000 title claims abstract 3
- 210000001035 gastrointestinal tract Anatomy 0.000 title claims 2
- 239000007787 solid Substances 0.000 claims abstract 27
- 239000002245 particle Substances 0.000 claims abstract 23
- 238000000034 method Methods 0.000 claims abstract 22
- 239000002702 enteric coating Substances 0.000 claims abstract 16
- 238000009505 enteric coating Methods 0.000 claims abstract 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 15
- 239000013543 active substance Substances 0.000 claims abstract 14
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract 4
- 229960003568 dexlansoprazole Drugs 0.000 claims abstract 4
- MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical group CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 claims abstract 4
- 239000002552 dosage form Substances 0.000 claims abstract 2
- 230000037406 food intake Effects 0.000 claims abstract 2
- 235000012054 meals Nutrition 0.000 claims abstract 2
- 229940126409 proton pump inhibitor Drugs 0.000 claims abstract 2
- 239000000612 proton pump inhibitor Substances 0.000 claims abstract 2
- 239000011241 protective layer Substances 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000000718 duodenal ulcer Diseases 0.000 claims 2
- 201000006549 dyspepsia Diseases 0.000 claims 2
- 239000008187 granular material Substances 0.000 claims 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims 2
- 208000016557 Acute basophilic leukemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 241000590002 Helicobacter pylori Species 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 206010034344 Peptic ulcer haemorrhage Diseases 0.000 claims 1
- 206010042220 Stress ulcer Diseases 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 201000008736 Systemic mastocytosis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 229920001577 copolymer Polymers 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 201000000052 gastrinoma Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000001288 gastroparesis Diseases 0.000 claims 1
- 208000024798 heartburn Diseases 0.000 claims 1
- 229940037467 helicobacter pylori Drugs 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- 229960003943 hypromellose Drugs 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
1. Способ лечения нарушения желудочно-кишечного тракта у пациента, нуждающегося в этом лечении, включающий стадии: ! введение указанному пациенту фармацевтической композиции, содержащей терапевтически эффективное количество лекарственной формы, включающей ингибитор протонного насоса, в котором указанную фармацевтическую композицию можно вводить пациенту независимо от приема пищи. ! 2. Способ лечения нарушения желудочно-кишечного тракта у пациента, нуждающегося в этом лечении, включающий стадии: ! введение указанному пациенту фармацевтической композиции, содержащей терапевтически эффективное количество: ! (a) первой твердой частицы, где указанная первая твердая частица содержит активный агент и первое энтеросолюбильное покрытие, причем первое энтеросолюбильное покрытие высвобождает активный агент из твердой частицы при pH от приблизительно 5,0 до приблизительно 5,5; и ! (b) второй твердой частицы, где указанная вторая твердая частица содержит активный агент и второе энтеросолюбильное покрытие, причем второе энтеросолюбильное покрытие высвобождает активный агент из твердой частицы при pH от приблизительно 6,2 до приблизительно 6,8; ! в котором первая твердая частица содержит от приблизительно 15 вес.% до приблизительно 50 вес.% фармацевтической композиции и вторая твердая частица содержит от приблизительно 50 вес.% до приблизительно 85 вес.% фармацевтической композиции; и ! дополнительно в котором указанную фармацевтическую композицию можно вводить пациенту независимо от приема пищи. ! 3. Способ по п.2, в котором активный агент в первой твердой частице представляет собой декслансопразол. ! 4. Способ по п.2, в котор�
Claims (18)
1. Способ лечения нарушения желудочно-кишечного тракта у пациента, нуждающегося в этом лечении, включающий стадии:
введение указанному пациенту фармацевтической композиции, содержащей терапевтически эффективное количество лекарственной формы, включающей ингибитор протонного насоса, в котором указанную фармацевтическую композицию можно вводить пациенту независимо от приема пищи.
2. Способ лечения нарушения желудочно-кишечного тракта у пациента, нуждающегося в этом лечении, включающий стадии:
введение указанному пациенту фармацевтической композиции, содержащей терапевтически эффективное количество:
(a) первой твердой частицы, где указанная первая твердая частица содержит активный агент и первое энтеросолюбильное покрытие, причем первое энтеросолюбильное покрытие высвобождает активный агент из твердой частицы при pH от приблизительно 5,0 до приблизительно 5,5; и
(b) второй твердой частицы, где указанная вторая твердая частица содержит активный агент и второе энтеросолюбильное покрытие, причем второе энтеросолюбильное покрытие высвобождает активный агент из твердой частицы при pH от приблизительно 6,2 до приблизительно 6,8;
в котором первая твердая частица содержит от приблизительно 15 вес.% до приблизительно 50 вес.% фармацевтической композиции и вторая твердая частица содержит от приблизительно 50 вес.% до приблизительно 85 вес.% фармацевтической композиции; и
дополнительно в котором указанную фармацевтическую композицию можно вводить пациенту независимо от приема пищи.
3. Способ по п.2, в котором активный агент в первой твердой частице представляет собой декслансопразол.
4. Способ по п.2, в котором активный агент во второй твердой частице представляет собой декслансопразол.
5. Способ по п.2, в котором активный агент в первой твердой частице и во второй твердой частице представляет собой декслансопразол.
6. Способ по п.2, в котором первое энтеросолюбильное покрытие имеет рН приблизительно 5,5.
7. Способ по п.6, в котором первое энтеросолюбильное покрытие содержит дисперсию сополимера метакриловой кислоты.
8. Способ по п.2, в котором второе энтеросолюбильное покрытие имеет рН приблизительно 6,75.
9. Способ по п.8, в котором второе энтеросолюбильное покрытие содержит смесь сополимера метакриловой кислоты типа B и сополимера метакриловой кислоты типа A в отношении 3:1.
10. Способ по п.2, в котором первая твердая частица содержит защитный слой между активным агентом и первым энтеросолюбильным покрытием.
11. Способ по п.2, в котором вторая твердая частица содержит защитный слой между активным агентом и вторым энтеросолюбильным покрытием.
12. Способ по п.10 или 11, в котором защитный слой представляет собой сахарозу, гипромеллозу, неэнтеросолюбильное покрытие или любую их комбинацию.
13. Способ по п.12, в котором неэнтеросолюбильное покрытие представляет собой гидроксипропилцеллюлозу.
14. Способ по п.2, в котором первая твердая частица содержит приблизительно 25% фармацевтической композиции, и вторая твердая частица содержит приблизительно 75% фармацевтической композиции.
15. Способ по п.2, в котором первая твердая частица представляет собой гранулу.
16. Способ по п.2, в котором вторая твердая частица представляет собой гранулу.
17. Способ по п.2, в котором фармацевтическая композиция представляет собой таблетку или капсулу.
18. Способ по п.2, в котором нарушение жедудочно-кишечного тракта представляет собой изжогу, воспалительную болезнь кишечника, болезнь Крона, синдром раздраженного кишечника, язвенный колит, пептическую язву, стрессовую язву, кровоточащую пептическую язву, дуоденальную язву, инфекционный энтерит, колит, дивертикулит, повышенную кислотность желудка, диспепсию, гастропарез, синдром Золлингера-Эллисона, гастроэзофагеальную рефлюксную болезнь, заболевание, вызванное Helicobacter pylori, синдром укороченной кишки, гиперсекреторные состояния, связанные с системным мастоцитозом или базофильным лейкозом, или гипергистаминемией, или комбинации любых из вышеупомянутых нарушений.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99875407P | 2007-10-12 | 2007-10-12 | |
| US60/998,754 | 2007-10-12 | ||
| US12/249,258 US8173158B2 (en) | 2007-10-12 | 2008-10-10 | Methods of treating gastrointestinal disorders independent of the intake of food |
| US12/249,258 | 2008-10-10 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013106514/15A Division RU2013106514A (ru) | 2007-10-12 | 2008-10-10 | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи |
| RU2014112070/15A Division RU2563993C1 (ru) | 2007-10-12 | 2014-03-28 | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010119041A true RU2010119041A (ru) | 2011-11-20 |
Family
ID=40534459
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010119041/15A RU2010119041A (ru) | 2007-10-12 | 2008-10-10 | Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи |
| RU2013106514/15A RU2013106514A (ru) | 2007-10-12 | 2008-10-10 | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи |
| RU2014112070/15A RU2563993C1 (ru) | 2007-10-12 | 2014-03-28 | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013106514/15A RU2013106514A (ru) | 2007-10-12 | 2008-10-10 | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи |
| RU2014112070/15A RU2563993C1 (ru) | 2007-10-12 | 2014-03-28 | Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8173158B2 (ru) |
| EP (1) | EP2203068A4 (ru) |
| JP (2) | JP5629581B2 (ru) |
| KR (3) | KR20170097787A (ru) |
| CN (2) | CN104069088A (ru) |
| AU (1) | AU2008310735B2 (ru) |
| BR (1) | BRPI0818286A2 (ru) |
| CA (1) | CA2702356C (ru) |
| CO (1) | CO6260019A2 (ru) |
| HK (1) | HK1202441A1 (ru) |
| IL (1) | IL204886B (ru) |
| MX (1) | MX2010003917A (ru) |
| MY (1) | MY153062A (ru) |
| RU (3) | RU2010119041A (ru) |
| SG (1) | SG185296A1 (ru) |
| WO (1) | WO2009049160A1 (ru) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1768668A2 (en) | 2004-06-16 | 2007-04-04 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
| BRPI0818286A2 (pt) * | 2007-10-12 | 2020-08-11 | Takeda Pharmaceuticals North America, Inc. | métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento. |
| EP2501383A4 (en) * | 2009-11-20 | 2013-06-26 | Handa Pharmaceuticals Llc | ORAL FORMULATION FOR DEXLANDSOPRAZOLE |
| CN102120030B (zh) * | 2010-01-08 | 2013-07-10 | 丽珠医药集团股份有限公司 | 一种艾普拉唑化学结构的药物及其用途 |
| US8563035B2 (en) * | 2010-05-05 | 2013-10-22 | Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi | Oral tablet compositions of dexlansoprazole |
| EP2384746A3 (en) * | 2010-05-05 | 2012-03-07 | Sanovel Ilac Sanayi ve Ticaret A.S. | Dual release oral tablet compositions of dexlansoprazole |
| EP2384745A3 (en) | 2010-05-05 | 2012-01-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Modified release pharmaceutical compositions of dexlansoprazole |
| US20120164233A1 (en) | 2010-07-30 | 2012-06-28 | Ranbaxy Laboratories Limited | Pulsatile release pharmaceutical formulation of dexlansoprazole |
| US9233103B2 (en) * | 2011-03-25 | 2016-01-12 | Takeda Pharmaceuticals U.S.A., Inc. | Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy |
| WO2013111149A1 (en) * | 2011-12-21 | 2013-08-01 | Hetero Research Foundation | Controlled release solid oral compositions of dexlansoprazole |
| CN102600109B (zh) * | 2012-04-13 | 2014-09-17 | 乐普药业股份有限公司 | 一种右兰索拉唑迟释胶囊及其制备方法 |
| CN105769824A (zh) * | 2014-12-16 | 2016-07-20 | 四川海思科制药有限公司 | 一种兰索拉唑缓释胶囊及其制备方法 |
| EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
| CN104940169B (zh) * | 2015-06-26 | 2017-10-10 | 山东省药学科学院 | 一种右兰索拉唑缓释胶囊及其制备方法 |
| US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
| BE1025137B1 (nl) * | 2017-12-22 | 2018-11-09 | Nutri-Ad International Nv | Diervoeder materiaal |
| KR102508141B1 (ko) * | 2019-07-01 | 2023-03-10 | 주식회사 연세대학교 바이오헬스기술지주회사 | 하이드로겔 및 egfr 리간드를 유효성분으로 포함하는 당 배출용 조성물 |
| CN112168965A (zh) * | 2019-07-05 | 2021-01-05 | 中国科学院生物物理研究所 | SRCAP ATPase激动剂在肠道干细胞自我更新受抑介导的疾病治疗中的应用 |
| WO2021236581A1 (en) * | 2020-05-18 | 2021-11-25 | Board Of Regents, The University Of Texas System | Granules for 3d printing technology |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2996431A (en) | 1953-12-16 | 1961-08-15 | Barry Richard Henry | Friable tablet and process for manufacturing same |
| US2957880A (en) | 1953-12-23 | 1960-10-25 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
| US4182756A (en) | 1977-11-21 | 1980-01-08 | Abbott Laboratories | High calorie solutions of low molecular weight glucose polymer mixtures useful for intravenous administration |
| US4464170A (en) | 1982-09-29 | 1984-08-07 | Miles Laboratories, Inc. | Blood glucose control apparatus and method |
| US4773907A (en) | 1982-12-20 | 1988-09-27 | Alza Corporation | Primary delivery system comprising secondary dosage form |
| DK58983D0 (da) | 1983-02-11 | 1983-02-11 | Leo Pharm Prod Ltd | Farmaceutisk praeparat |
| US4783337A (en) | 1983-05-11 | 1988-11-08 | Alza Corporation | Osmotic system comprising plurality of members for dispensing drug |
| JPS60100516A (ja) | 1983-11-04 | 1985-06-04 | Takeda Chem Ind Ltd | 徐放型マイクロカプセルの製造法 |
| US4777049A (en) | 1983-12-01 | 1988-10-11 | Alza Corporation | Constant release system with pulsed release |
| US4894240A (en) | 1983-12-22 | 1990-01-16 | Elan Corporation Plc | Controlled absorption diltiazem formulation for once-daily administration |
| JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
| US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
| GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
| DE3684446D1 (de) | 1985-12-28 | 1992-04-23 | Sumitomo Pharma | Arzneimittel mit verzoegerter stossweiser freisetzung. |
| CA1327010C (en) | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
| US5433959A (en) | 1986-02-13 | 1995-07-18 | Takeda Chemical Industries, Ltd. | Stabilized pharmaceutical composition |
| US4904476A (en) | 1986-03-04 | 1990-02-27 | American Home Products Corporation | Formulations providing three distinct releases |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| GB2189699A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| IE58401B1 (en) | 1986-06-20 | 1993-09-08 | Elan Corp Plc | Controlled absorption pharmaceutical composition |
| US5330982A (en) | 1986-12-17 | 1994-07-19 | Glaxo Group Limited | Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith |
| IT1201136B (it) | 1987-01-13 | 1989-01-27 | Resa Farma | Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive |
| US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
| DK171989B1 (da) | 1987-08-04 | 1997-09-08 | Takeda Chemical Industries Ltd | Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler |
| EP0439453B1 (en) | 1987-10-12 | 1994-01-19 | Exomed Australia Pty. Ltd. (ACN 051 976 446) | Improved method for treatment of gastrointestinal disorders |
| DE3822095A1 (de) | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| SE8903914D0 (sv) * | 1989-11-22 | 1989-11-22 | Draco Ab | Oral composition for the treatment of inflammatory bowel diseases |
| FR2655266B1 (fr) | 1989-12-05 | 1992-04-03 | Smith Kline French Lab | Compositions pharmaceutiques a base de cimetidine. |
| US5229131A (en) | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| US5264223A (en) | 1990-03-29 | 1993-11-23 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
| IT1246382B (it) * | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| GB2253346A (en) * | 1991-02-22 | 1992-09-09 | John Rhodes | Delayed release oral dosage forms for treatment of intestinal disorders |
| IL99699A (en) | 1990-10-10 | 2002-04-21 | Autoimmune Inc | Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes |
| DE4035455A1 (de) | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | Enantiomerentrennung |
| JP2552937Y2 (ja) | 1991-05-18 | 1997-11-05 | 株式会社堀場製作所 | 磁気式酸素分析装置 |
| US5178867A (en) | 1991-08-19 | 1993-01-12 | Alza Corporation | Dosage form for delivering drug in short-time period |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5262173A (en) | 1992-03-02 | 1993-11-16 | American Cyanamid Company | Pulsatile once-a-day delivery systems for minocycline |
| US5582837A (en) | 1992-03-25 | 1996-12-10 | Depomed, Inc. | Alkyl-substituted cellulose-based sustained-release oral drug dosage forms |
| US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
| JP3277342B2 (ja) | 1992-09-02 | 2002-04-22 | 武田薬品工業株式会社 | 徐放性マイクロカプセルの製造法 |
| US5431917A (en) | 1992-10-08 | 1995-07-11 | Japan Elanco Company, Ltd. | Hard capsule for pharmaceutical drugs and method for producing the same |
| US5260069A (en) * | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
| US5656290A (en) | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
| JP4389005B2 (ja) | 1993-11-02 | 2009-12-24 | ユー．ディー．テスティング．インコーポレイテッド | 患者が薬剤処方に従っているかどうかをモニターする方法 |
| CZ289804B6 (cs) | 1994-07-08 | 2002-04-17 | Astrazeneca Ab | Multijednotková tabletovaná dávková forma I |
| SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
| SE504459C2 (sv) | 1994-07-15 | 1997-02-17 | Astra Ab | Förfarande för framställning av substituerade sulfoxider |
| PE32296A1 (es) | 1994-07-28 | 1996-08-07 | Hoffmann La Roche | Ester de l-monovalina derivado de 2-(2-amino-1,6-dihidro-6-oxo-purin-9-il) metoxi-1,3-propandiol y sus sales farmaceuticamente aceptables |
| US5516351A (en) | 1994-08-05 | 1996-05-14 | Recycled Glass Products, Inc. | Foamed glass manufacture |
| US5834024A (en) | 1995-01-05 | 1998-11-10 | Fh Faulding & Co. Limited | Controlled absorption diltiazem pharmaceutical formulation |
| US5616707A (en) | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| US5945124A (en) | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
| US5807577A (en) | 1995-11-22 | 1998-09-15 | Lab Pharmaceutical Research International Inc. | Fast-melt tablet and method of making same |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| US5773031A (en) | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
| US6096339A (en) | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
| US5817388A (en) | 1996-11-08 | 1998-10-06 | Carl M. Rodia & Associates | Multi-component dye compositions for optical recording media |
| WO1998029095A2 (en) | 1997-01-03 | 1998-07-09 | Elan Corporation, Plc | Sustained release cisapride mini-tablet formulation |
| US6162463A (en) | 1997-05-01 | 2000-12-19 | Dov Pharmaceutical Inc | Extended release formulation of diltiazem hydrochloride |
| SE510650C2 (sv) | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
| US6635280B2 (en) | 1997-06-06 | 2003-10-21 | Depomed, Inc. | Extending the duration of drug release within the stomach during the fed mode |
| US5889051A (en) * | 1997-07-15 | 1999-03-30 | Development Center For Biotechnology | Stabilization of prostaglandin drug |
| DE19755682A1 (de) | 1997-12-15 | 1999-06-17 | Knoll Ag | Verfahren zur Ermittlung eines Dosierungschemas für Thrombininhibitoren |
| SE9704869D0 (sv) | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulaton II |
| SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
| WO1999038513A1 (en) | 1998-01-30 | 1999-08-05 | Sepracor Inc. | R-lansoprazole compositions and methods |
| JP4127740B2 (ja) | 1998-04-20 | 2008-07-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 安定化したベンズイミダゾール系化合物含有組成物 |
| DE19820529A1 (de) | 1998-05-08 | 1999-11-11 | Lohmann Therapie Syst Lts | Wirkstoff enthaltende orale und mucosale Zubereitung mit steuerbarer Wirkstofffreisetzung und ihre Verwendung |
| JP3746167B2 (ja) | 1998-05-18 | 2006-02-15 | 武田薬品工業株式会社 | 医薬製剤 |
| ZA9810765B (en) | 1998-05-28 | 1999-08-06 | Ranbaxy Lab Ltd | Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole. |
| JP3449253B2 (ja) | 1998-10-29 | 2003-09-22 | シオノギクオリカプス株式会社 | 硬質カプセルの製造方法 |
| TWI275587B (en) | 1999-06-17 | 2007-03-11 | Takeda Chemical Industries Ltd | A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole |
| JP2001122769A (ja) | 1999-10-22 | 2001-05-08 | Lion Corp | 固形製剤及び固形製剤の崩壊・溶出性改善方法 |
| CA2407208C (en) | 2000-04-28 | 2010-08-17 | Takeda Chemical Industries, Ltd. | Process for producing optically active sulfoxide derivative |
| WO2001087874A1 (en) | 2000-05-15 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Process for producing crystal |
| IT1318625B1 (it) | 2000-07-14 | 2003-08-27 | Roberto Valducci | Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente. |
| EP1306375B1 (en) | 2000-08-04 | 2006-10-11 | Takeda Pharmaceutical Company Limited | Salts of benzimidazole compound and application thereof |
| EP1337525B8 (en) | 2000-12-01 | 2011-10-05 | Takeda Pharmaceutical Company Limited | Process for the crystallization of (r)- or (s)-lansoprazole |
| BR0115986A (pt) | 2000-12-07 | 2003-12-23 | Altana Pharma Ag | Comprimido de desintegração rápida contendo um ingrediente ativo instável aos ácidos |
| CA2403670C (en) * | 2001-01-31 | 2010-02-09 | Rohm Gmbh & Co. Kg | Multiparticulate drug form comprising at least two differently coated pellet forms |
| CN100562317C (zh) | 2001-10-17 | 2009-11-25 | 武田药品工业株式会社 | 含大量酸不稳定药物的颗粒 |
| US20030091630A1 (en) | 2001-10-25 | 2003-05-15 | Jenny Louie-Helm | Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data |
| JP4493970B2 (ja) * | 2002-10-16 | 2010-06-30 | 武田薬品工業株式会社 | 持続性製剤 |
| CN1713897B (zh) * | 2002-10-16 | 2012-07-04 | 武田药品工业株式会社 | 控释制剂 |
| EP1552833B1 (en) * | 2002-10-16 | 2016-12-28 | Takeda Pharmaceutical Company Limited | Process for producing an amorphous optically active isomer of lansoprazole |
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| US20040146558A1 (en) | 2003-01-28 | 2004-07-29 | Kyowa Pharmaceutical Co., Ltd. | Oral enteric-coated preparation |
| CA2518780C (en) * | 2003-03-12 | 2014-05-13 | Takeda Pharmaceutical Company Limited | Drug composition having active ingredient adhered at high concentration to spherical core |
| JP4578124B2 (ja) * | 2003-03-12 | 2010-11-10 | 武田薬品工業株式会社 | 高濃度に活性成分を球形核に付着させた医薬組成物 |
| WO2004082665A1 (ja) | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | 放出制御組成物 |
| EP1721604A4 (en) * | 2004-03-04 | 2008-04-30 | Takeda Pharmaceutical | STABLE CAPSULE PREPARATION |
| US20050226929A1 (en) | 2004-04-12 | 2005-10-13 | Jianbo Xie | Controlled release opioid analgesic formulation |
| EP1768668A2 (en) | 2004-06-16 | 2007-04-04 | Tap Pharmaceutical Products, Inc. | Multiple ppi dosage form |
| EP1621187A1 (en) * | 2004-07-26 | 2006-02-01 | AstraZeneca AB | Pharmaceutical multiparticulate tablet formulations and process for their preparation |
| US20060024362A1 (en) | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
| FR2878161B1 (fr) | 2004-11-23 | 2008-10-31 | Flamel Technologies Sa | Forme medicamenteuse orale, solide et concue pour eviter le mesusage |
| US7803817B2 (en) * | 2005-05-11 | 2010-09-28 | Vecta, Ltd. | Composition and methods for inhibiting gastric acid secretion |
| FR2885526B1 (fr) | 2005-05-13 | 2007-07-27 | Flamel Technologies Sa | Medicament oral a base d'inhibiteur de pompe a protons |
| DE102005024614A1 (de) | 2005-05-25 | 2006-11-30 | Röhm Gmbh | Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug |
| DE102005032806A1 (de) | 2005-07-12 | 2007-01-18 | Röhm Gmbh | Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten |
| US20070026071A1 (en) * | 2005-07-28 | 2007-02-01 | Qpharma, Llc | Magnesium salt proton pump inhibitor dosage forms |
| FR2891459B1 (fr) | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| BRPI0818286A2 (pt) * | 2007-10-12 | 2020-08-11 | Takeda Pharmaceuticals North America, Inc. | métodos de tratamento de distúrbios gastrointestinais independente da ingestão de alimento. |
| US20090263475A1 (en) * | 2008-04-21 | 2009-10-22 | Nagaraju Manne | Dexlansoprazole compositions |
| US20110189271A1 (en) * | 2010-02-02 | 2011-08-04 | Vishal Lad | Pharmaceutical formulations of acid-labile drugs |
| JP5819329B2 (ja) * | 2010-03-09 | 2015-11-24 | アルカーメス ファーマ アイルランド リミテッド | アルコール耐性腸溶性医薬組成物 |
| US8563035B2 (en) * | 2010-05-05 | 2013-10-22 | Sanovel Ilac Sanayi Ve Ticaret Anomin Sirketi | Oral tablet compositions of dexlansoprazole |
| EP2384745A3 (en) * | 2010-05-05 | 2012-01-18 | Sanovel Ilac Sanayi ve Ticaret A.S. | Modified release pharmaceutical compositions of dexlansoprazole |
| EP2384746A3 (en) * | 2010-05-05 | 2012-03-07 | Sanovel Ilac Sanayi ve Ticaret A.S. | Dual release oral tablet compositions of dexlansoprazole |
-
2008
- 2008-10-10 BR BRPI0818286-8A patent/BRPI0818286A2/pt not_active Application Discontinuation
- 2008-10-10 EP EP08837108A patent/EP2203068A4/en not_active Ceased
- 2008-10-10 CA CA2702356A patent/CA2702356C/en active Active
- 2008-10-10 AU AU2008310735A patent/AU2008310735B2/en active Active
- 2008-10-10 WO PCT/US2008/079520 patent/WO2009049160A1/en not_active Ceased
- 2008-10-10 SG SG2012075891A patent/SG185296A1/en unknown
- 2008-10-10 KR KR1020177022749A patent/KR20170097787A/ko not_active Ceased
- 2008-10-10 MX MX2010003917A patent/MX2010003917A/es active IP Right Grant
- 2008-10-10 KR KR1020157013260A patent/KR20150084013A/ko not_active Ceased
- 2008-10-10 KR KR1020107010478A patent/KR20100116165A/ko not_active Ceased
- 2008-10-10 RU RU2010119041/15A patent/RU2010119041A/ru not_active Application Discontinuation
- 2008-10-10 CN CN201410289597.6A patent/CN104069088A/zh active Pending
- 2008-10-10 RU RU2013106514/15A patent/RU2013106514A/ru not_active Application Discontinuation
- 2008-10-10 CN CN2008801191827A patent/CN102014638A/zh active Pending
- 2008-10-10 JP JP2010529082A patent/JP5629581B2/ja active Active
- 2008-10-10 MY MYPI20101591 patent/MY153062A/en unknown
- 2008-10-10 US US12/249,258 patent/US8173158B2/en active Active
-
2010
- 2010-04-06 IL IL204886A patent/IL204886B/en active IP Right Grant
- 2010-04-12 CO CO10041742A patent/CO6260019A2/es not_active Application Discontinuation
-
2013
- 2013-08-19 JP JP2013169403A patent/JP2014012692A/ja active Pending
-
2014
- 2014-03-28 RU RU2014112070/15A patent/RU2563993C1/ru active
-
2015
- 2015-03-27 HK HK15103105.9A patent/HK1202441A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2203068A4 (en) | 2012-08-22 |
| BRPI0818286A2 (pt) | 2020-08-11 |
| MY153062A (en) | 2014-12-31 |
| CN102014638A (zh) | 2011-04-13 |
| JP5629581B2 (ja) | 2014-11-19 |
| AU2008310735B2 (en) | 2013-09-12 |
| RU2013106514A (ru) | 2015-03-10 |
| WO2009049160A1 (en) | 2009-04-16 |
| KR20150084013A (ko) | 2015-07-21 |
| CA2702356A1 (en) | 2009-04-16 |
| JP2014012692A (ja) | 2014-01-23 |
| RU2563993C1 (ru) | 2015-09-27 |
| US20090098199A1 (en) | 2009-04-16 |
| IL204886A0 (en) | 2010-11-30 |
| KR20170097787A (ko) | 2017-08-28 |
| HK1202441A1 (en) | 2015-10-02 |
| CA2702356C (en) | 2014-02-11 |
| SG185296A1 (en) | 2012-11-29 |
| JP2011500595A (ja) | 2011-01-06 |
| US8173158B2 (en) | 2012-05-08 |
| CO6260019A2 (es) | 2011-03-22 |
| EP2203068A1 (en) | 2010-07-07 |
| AU2008310735A1 (en) | 2009-04-16 |
| CN104069088A (zh) | 2014-10-01 |
| KR20100116165A (ko) | 2010-10-29 |
| MX2010003917A (es) | 2012-09-28 |
| IL204886B (en) | 2018-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010119041A (ru) | Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи | |
| JP2011500595A5 (ru) | ||
| Lee et al. | Randomised phase 3 trial: tegoprazan, a novel potassium‐competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis | |
| Maradey-Romero et al. | New and future drug development for gastroesophageal reflux disease | |
| Patel et al. | AGA clinical practice update on integrating potassium-competitive acid blockers into clinical practice: expert review | |
| Malfertheiner et al. | Peptic ulcer disease | |
| Wong et al. | Potassium-competitive acid blockers: present and potential utility in the armamentarium for acid peptic disorders | |
| Wang et al. | Current pharmacological management of gastroesophageal reflux disease | |
| Wallace et al. | Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease | |
| Hammer et al. | Effect of splitting the dose of esomeprazole on gastric acidity and nocturnal acid breakthrough | |
| JP2008534438A5 (ru) | ||
| RU2013141534A (ru) | Составы l-ментола, состоящие из множества частиц, и связанные с ними способы | |
| Mössner et al. | Developments in the inhibition of gastric acid secretion | |
| TW200509923A (en) | A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid | |
| JP2016164165A5 (ru) | ||
| CA2318008A1 (en) | Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound | |
| Baldwin et al. | Rabeprazole: a review of its use in the management of gastric acid-related diseases in adults | |
| KR20100111040A (ko) | 지방산 계열 화합물을 유효성분으로 함유하는 위장 질환 예방 또는 치료용 조성물 | |
| Metz et al. | Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis | |
| KR20250090275A (ko) | 벤즈이미다졸 유도체 화합물을 포함하는 약학적 조성물 | |
| CA2605839A1 (en) | Stabilized composition of a proton pump inhibitor | |
| JP2011520868A5 (ru) | ||
| Inamori et al. | Early effects of lafutidine or rabeprazole on intragastric acidity: which drug is more suitable for on-demand use? | |
| WO2004098599A2 (en) | Proton pump inhibitors for the treatment of lower abdominal disorders | |
| Saber et al. | Age-related gastric changes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20131028 |